Lace To Helm New RQM+ Reimbursement Division
RQM+, a global MedTech regulatory and quality service provider, has launched a reimbursement division to provide its clients with reimbursement services, in addition to regulatory, quality, clinical and laboratory services, throughout the medical device and diagnostics product lifecycle. Daniel Lace, MD, will lead the new division and serve as chief medical officer (CMO) of RQM+.
Dr. Lace has more than 25 years of leadership experience as a healthcare executive across a wide range of managed care, pharmaceutical, device, diagnostic and consulting businesses. He has served as CMO and has held senior leadership positions in global pharmaceutical and medical device companies, as well as national managed care organizations.
“MedTech manufacturers are seeking reimbursement partners to manage increasingly complex challenges and ensure that reimbursement strategies are developed in tandem with regulatory strategies,” said Margaret Keegan, CEO of RQM+. “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”
“It is a privilege to serve as CMO—providing strategic guidance for reimbursement as well as related services and technologies,” said Dr. Lace. “We look forward to helping customers navigate the complicated reimbursement and market access environment. We will use our extensive experience with the latest reimbursement requirements and value-based compensation models, as well as key payment trends, to provide customized support that fits each company’s needs.”
Related Articles
-
“Approaches to Increasing Diversity in Clinical Research and Addressing Health Inequities” offers key recommendations for device manufacturers and developers on steps they can take to increase diversity in clinical research and address health equity.
-
Market research and forecasting help ensure that you are investing in a device or drug that is needed and will be well received. In this article, Sanobar Syed, Associate Director of Forecasting, Market Insights and Strategies, BeiGene, highlights strategies to…
-
AI not only improves data collection and analysis, it impacts which products are engaged in clinical trials, determines necessary medical criteria, helps design the trials and can even choose the best participating facilities. The result is, organizations that leverage AI…
-
Business strategy and forecasting influence several functional areas within an organization, including R&D, pipeline planning, revenue planning, inventory, resource and budget allocation, project prioritization, compensation plans, market access efforts, and more. These varied uses reflect the first major challenge of…
